PEPTIDE DATABASE

Lixisenatide

Adlyxin; Lyxumia

A peptide GLP-1 receptor agonist used clinically for treatment of type 2 diabetes in some jurisdictions.

GLP-1 receptor agonist Established clinical compound Approved prescription drug in certain jurisdictions

COMPOUND DATA

Molecular Information

Classification GLP-1 receptor agonist

Molecular Weight Not available

Molecular Formula Not available

Research Status Established clinical compound

BIOLOGICAL ATLAS

Systems Associated With Lixisenatide

Brain & CNS

Approved / Established

Established pharmacological pathway

GLP-1 receptor agonist studied extensively in gastrointestinal and glucose-regulatory physiology.

Gastrointestinal

Approved / Established

Established pharmacological pathway

GLP-1 receptor agonist studied extensively in gastrointestinal and glucose-regulatory physiology.

Pancreas & Glucose

Approved / Established

Established pharmacological pathway

GLP-1 receptor agonist studied extensively in gastrointestinal and glucose-regulatory physiology.

Metabolic

Approved / Established

Established pharmacological pathway

GLP-1 receptor agonist studied extensively in gastrointestinal and glucose-regulatory physiology.

Endocrine & Hormonal

Approved / Established

Established pharmacological pathway

GLP-1 receptor agonist studied extensively in gastrointestinal and glucose-regulatory physiology.

STATUS

Regulatory Information

Approved prescription drug in certain jurisdictions

Regulatory status can vary by jurisdiction and may change over time.

HAXBIO COMMUNITY

Lixisenatide Discussions & News

No community posts yet Nothing about Lixisenatide has been posted yet.

HaxBio provides information for educational and research purposes. Information on this page should not be interpreted as medical advice.